Nationale-Nederlanden Powszechne Towarzystwo Emerytalne’s Protagonist Therapeutics PTGX Stock Holding History

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-571,825	Closed	-$60.3M	–	52
2026 Q1	$60.3M	Hold	571,825	–	–	5.11%	4
2025 Q4	$49.9M	Buy	+571,825	New	+$46.8M	4.43%	7

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne's PTGX Position: Q2 2026 in Review

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 571,825 shares — an estimated $60.3M sold.

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne first reported a position in PTGX in Q4 2025 and held it in 2 quarters. The position peaked at $60.3M in Q1 2026. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne sold 571,825 Protagonist Therapeutics shares in Q2 2026, an estimated $60.3M.
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne first reported a position in Protagonist Therapeutics in Q4 2025 and held it in 2 quarters.
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne's Protagonist Therapeutics position peaked at $60.3M in Q1 2026.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Nationale-Nederlanden Powszechne Towarzystwo Emerytalne's 13F filing for Q2 2026, filed 7 Aug 2026.